Double punch: CAR-T cells followed by antibodies may boost lymphoma remission

NCT ID NCT04889716

Recruiting now Disease control Sponsor: Abramson Cancer Center at Penn Medicine Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether giving additional antibody drugs (mosunetuzumab or glofitamab plus obinutuzumab) after CAR-T cell therapy can improve outcomes for people with relapsed or refractory large B-cell lymphoma. About 23 participants will receive the combination to see if it leads to complete remission at 24 weeks. The goal is to target cancer cells more effectively without increasing serious side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: mosunetuzumab, glofitamab, obinutuzumab
What this could lead to: If successful, this approach could help more people with hard-to-treat lymphoma achieve long-term remission after CAR-T therapy.
What could go wrong: This is a small, early-phase trial (23 participants) testing safety and effectiveness. Side effects like cytokine release syndrome are possible, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DLBCL - DIFFUSE LARGE B CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diffuse large B-cell lymphoma follicular lymphoma interdigitating dendritic cell sarcoma large B-cell lymphoma relapsed/refractory diffuse large B-cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DLBCL - DIFFUSE LARGE B CELL LYMPHOMA LARGE B-CELL LYMPHOMA

Contacts and locations

Locations

Abramson Cancer Center of the University of Pennsylvania
RECRUITING

Philadelphia, Pennsylvania, 19104, United States
University of Nebraska Medical Center
RECRUITING

Omaha, Nebraska, 68198, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.